Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hodgkin Disease × Lenograstim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 179 fludarabine phosphate 107 Etoposide 100 Peripheral Blood Stem Cell Transplantation 91 Filgrastim 83 Mycophenolic Acid 81 Doxorubicin 78 Whole-Body Irradiation 74 Melphalan 73 Brentuximab Vedotin 70 Radiotherapy 69 Tacrolimus 67 fludarabine 64 Busulfan 64 Vinblastine 59 Cyclosporine 58 Rituximab 56 Dacarbazine 49 Gemcitabine 48 Granulocyte Colony-Stimulating Factor 47 Bleomycin 47 Vincristine 43 Antilymphocyte Serum 43 Prednisone 41 Cytarabine 41 Nivolumab 40 Methotrexate 39 Carmustine 34 pembrolizumab 31 Sirolimus 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡